The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary hypertension (PH).
Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study) / Pan, Z.; Marra, A. M.; Benjamin, N.; Eichstaedt, C. A.; Blank, N.; Bossone, E.; Cittadini, A.; Coghlan, G.; Denton, C. P.; Distler, O.; Egenlauf, B.; Fischer, C.; Harutyunova, S.; Xanthouli, P.; Lorenz, H. -M.; Grunig, E.. - In: ARTHRITIS RESEARCH & THERAPY. - ISSN 1478-6362. - 21:1(2019), p. 217. [10.1186/s13075-019-1981-0]
Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)
Marra A. M.Co-primo
;Bossone E.;Cittadini A.;
2019
Abstract
The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary hypertension (PH).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
